Lung (Non-Small Cell) Cancer: E4512 (Iowa Cancer Specialists)

ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein


The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for patients with ALK-positive non-small cell lung cancer.

The study drug, crizotinib, is already FDA-approved for use in ALK-positive locally advanced or metastatic (spread to other areas of the body) non-small lung cancer. The use of crizotinib in this study is investigational (not approved by the FDA) because crizotinib (or placebo) will be prescribed for earlier stage disease after the cancer has been surgically removed.

This study is related to the following study - A151216.

For more information, please visit the National Cancer Institute.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Lung (Non-Small Cell)
Eastern Cooperative Oncology Group
Kim Turner, R.N. at 563-421-1908


  • Genesis Cancer Care Institute
    1351 West Central Park Avenue
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office